Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.43 |
| ▸ | HTT | P42858 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366369 | 0.90 | HTT (0.45) | LMNAHTTMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2366967 | 0.87 | LMNA (0.44) | LMNAHTTMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2365931 | 0.87 | SLC6A9 (0.39) | LMNAHTTMAPTSMN1; SMN2TP53 | |
| SCHEMBL2366759 | 0.87 | LMNA (0.43) | LMNAHTTMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14686437 | 0.86 | LMNA (0.45) | LMNAHTTMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2366039 | 0.85 | HTT (0.47) | LMNAHTTMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2365999 | 0.84 | HTT (0.55) | LMNAHTTMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2365990 | 0.84 | HTT (0.55) | LMNAHTTMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2366348 | 0.84 | MEN1 (0.32) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2365872 | 0.83 | GPR119 (0.41) | LMNAMAPTPOLBTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | LMNA 3668/4885HTT 1580/4885MAPT 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.